HCPLive

Related Tags

New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Click here to view this article.


Most Popular

Recommended Reading

For women with breast cancer, embryo cryopreservation after aromatase inhibitor treatment and ovarian stimulation preserves fertility, according to a study published online June 22 in the Journal of Clinical Oncology.

Glucocorticoids and other 3-ketosteroids may adversely affect patients with mixed estrogen receptor (ER) α-positive/cytokeratin-5 (CK5) breast cancer, according to a study published online June 22 in Oncogene.

For breast cancer survivors, a yoga and meditation intervention is associated with improvement in menopausal symptoms, according to a study published in the July 1 issue of Cancer.

The percentage of women with early-stage breast cancer who undergo breast-conserving therapy (BCT) has risen slowly in recent years, new research shows.
$vAR$